Role of Red Blood Cells in Cardiovascular Disease
NCT07151222 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2025-09-03
Summary
The risk of myocardial infarction is dependent on cardiovascular risk factors including type 2 diabetes (T2D) but underlying mechanisms are poorly understood. We identified that red blood cells (RBCs) mediate beneficial cardiovascular regulatory effects under hypoxic/ischemic conditions via signaling by nitric oxide (NO) and soluble guanylate cyclase (sGC) in the RBCs. The RBCs become dysregulated in T2D which induces endothelial and cardiac injury. This project investigates the signaling of RBCs in cardiovascular disease and explores novel therapeutic strategies that target RBC function in myocardial infarction and T2D.
Aims To determine the
* mechanisms behind cardioprotective effect of RBCs in myocardial infarction
* signaling behind cardiovascular injury induced by RBCs in T2D
Work plan RBCs collected from patients with myocardial infarction, patients with T2D and healthy controls are investigated in bioassays including isolated hearts of ischemia/reperfusion, endothelial function and cell cultures. Molecular mechanisms behind the effects of RBCs are identified with focus on the NO-sGC pathway in the RBCs.
This project unravels the RBC as a mediator of cardiovascular disease and has the potential to identify novel therapeutic strategies by targeting RBC signaling.
Conditions
Sponsors & Collaborators
-
Karolinska University Hospital
collaborator OTHER - lead OTHER
Principal Investigators
-
John Pernow, MD · Karolinska Institutet
Eligibility
- Min Age
- 25 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-01-01
- Primary Completion
- 2030-12-30
- Completion
- 2031-12-30
Countries
- Sweden
Study Locations
More Related Trials
-
Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling
NCT01538771 ·Status: COMPLETED ·Phase: PHASE2
-
Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers
NCT02290080 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of Nitroglycerin for Field Treatment of STEMI
NCT02407002 ·Status: COMPLETED
-
Local Thrombolytics Before Thrombectomy in STEMI
NCT01568931 ·Status: UNKNOWN ·Phase: PHASE4
-
Intravenous Streptokinase in Acute Myocardial Infarction
NCT00000507 ·Status: COMPLETED ·Phase: PHASE3
-
Outcome of Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients
NCT01623700 ·Status: UNKNOWN
-
Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus
NCT01475552 ·Status: COMPLETED ·Phase: PHASE4
-
Nitric Oxide in Myocardial Infarction Size
NCT00568061 ·Status: TERMINATED ·Phase: PHASE2
-
A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction
NCT07306182 ·Status: RECRUITING ·Phase: PHASE2
-
Protective Effect of Coronary Collaterals on Infarct Size in Patients With Acute Myocardial Infarction
NCT00412672 ·Status: WITHDRAWN
-
Inflammatory and Hematological Indices in Diabetic STEMI Patients Undergoing Primary PCI
NCT07155395 ·Status: NOT_YET_RECRUITING
-
Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction
NCT03037229 ·Status: COMPLETED
-
Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
NCT04688723 ·Status: UNKNOWN ·Phase: PHASE4
-
External Validation of Ischemia and Hemorrhage Risk Models in Patients With Coronary Heart Disease
NCT07295665 ·Status: NOT_YET_RECRUITING
-
Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
NCT04899479 ·Status: RECRUITING ·Phase: PHASE4
-
Long Term Clinical Efficacy of Thrombectomy Devices in Acute ST Elevation Myocardial Infarction
NCT00766740 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of rhBNP on CMD in Patients With STEMI After PPCI
NCT05723315 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART
NCT02311231 ·Status: COMPLETED ·Phase: PHASE4
-
Rituximab in Patients With Acute ST-elevation Myocardial Infarction Study
NCT03072199 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Drug Elution and Distal Protection During Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction
NCT00192868 ·Status: UNKNOWN ·Phase: NA
-
Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size
NCT01882179 ·Status: COMPLETED ·Phase: PHASE3
-
Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes
NCT03113773 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention
NCT01757457 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction
NCT00806403 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Slow-flow After Primary Percutaneous Coronary Intervention With Flow-mediated Hyperemia
NCT04685941 ·Status: COMPLETED ·Phase: NA